How Argenx Scaled to $4 Billion Without Bureaucracy

Biotech companies face the same dilemma as businesses in other industries: Innovation drops off dramatically with scale. European biotech Argenx has reached a market value of more than $40 billion, having so far escaped that innovation trap. How has it done this? The company shuns hierarchy and instead organizes into small teams, each dedicated to fighting a single disease with a laser focus on bringing value to the patient.

“Humans can have incredible impact when you allow them to,” said Argenx’s incoming CEO, Karen Massey.

В этом эпизоде Лидеры всех уровней, she explains how the company manages to retain the nimbleness of a startup.

The Argenx Playbook: Borrow These Ideas

• Use no budgets — only plans — to keep teams focused on the right priorities.
• Stop counting layers of management and try Argenx’s alternative. Fight the urge to give quick answers and maintain curiosity as a leader.

Listen as hosts Kate W. Isaacs and Michele Zanini dig into the details of how Argenx uses distributed leadership to maintain its innovative edge and uncover insights that you can apply in your own organization.

Видеокредиты

Karen Massey is the incoming CEO of Argenx.

Кейт В. Айзекс Старший преподаватель Школы менеджмента Слоуна Массачусетского технологического института.

Микеле Дзанини is coauthor of the Wall Street Journal бестселлер Гуманократия (Harvard Business Review Press, 2020).

M. Шон Рид является мультимедийным редактором в MIT Sloan Management Review.